EYLEA 40 mg/ml Solution for injection Ref.[6096] Active ingredients: Aflibercept

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Bayer AG, 51368, Leverkusen, Germany

Product name and form

Eylea 40 mg/ml solution for injection in a vial.

Pharmaceutical Form

Solution for injection (injection).

The solution is a clear, colourless to pale yellow and iso-osmotic solution.

Qualitative and quantitative composition

1 mL solution for injection contains 40 mg aflibercept*.

One vial contains an extractable volume of at least 0.1 mL, equivalent to at least 4 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept.

* Fusion protein consisting of portions of human VEGF (Vascular Endothelial Growth Factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Aflibercept

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

List of Excipients

Polysorbate 20
Sodium dihydrogen phosphate, monohydrate (for pH adjustment)
Disodium hydrogen phosphate, heptahydrate (for pH adjustment)
Sodium chloride
Sucrose
Water for injection

Pack sizes and marketing

Solution in a vial (type I glass) with a stopper (elastomeric rubber), and an 18 G filter needle. Each vial contains an extractable volume of at least 0.1 mL. Pack size of 1 vial + 1 filter needle.

Marketing authorization holder

Bayer AG, 51368, Leverkusen, Germany

Marketing authorization dates and numbers

EU/1/12/797/002

Date of first authorisation: 22 November 2012
Date of latest renewal: 13 July 2017

Drugs

Drug Countries
EYLEA Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.